ライフサイエンスコーパス: cell transplantation

1 en-specific responses in the context of stem cell transplantation.

2 aft-versus-myeloma effect of allogeneic stem cell transplantation.

3 ortality and morbidity after allogeneic stem-cell transplantation.

4 ultiple myeloma who were ineligible for stem-cell transplantation.

5 en-specific responses via hematopoietic stem cell transplantation.

6 -refractory acute GVHD after allogeneic stem-cell transplantation.

7 corrected with allogeneic hematopoietic stem cell transplantation.

8 penia and solid organ and hematopoietic stem cell transplantation.

9 homa who were ineligible for autologous stem-cell transplantation.

10 n the field of allogeneic hematopoietic stem cell transplantation.

11 corrected with allogeneic hematopoietic stem cell transplantation.

12 ous modality of cultivated limbal epithelial cell transplantation.

13 nts who are not eligible for autologous stem-cell transplantation.

14 nhibitors, and autologous or allogeneic stem cell transplantation.

15 Thirteen participants proceeded to stem-cell transplantation.

16 limitation of allogeneic hematopoietic stem cell transplantation.

17 nzapine in the setting of hematopoietic stem cell transplantation.

18 compatibility Working Group in Hematopoietic Cell Transplantation.

19 ortality after allogeneic hematopoietic stem cell transplantation.

20 ML cured after allogeneic hematopoietic stem cell transplantation.

21 gression after autologous hematopoietic stem-cell transplantation.

22 thout censoring for allogeneic hematopoietic cell transplantation.

23 /PV myelofibrosis undergoing allogeneic stem cell transplantation.

24 es with chemotherapy without undergoing stem-cell transplantation.

25 ogous and even allogeneic hematopoietic stem cell transplantation.

26 autologous or allogeneic hematopoietic stem cell transplantation.

27 these patients, 45% went on to undergo stem-cell transplantation.

28 therapy in the setting of hematopoietic stem cell transplantation.

29 regeneration of vitalized pulp via pulp stem cell transplantation.

30 conditioning regimens for hematopoietic stem cell transplantation.

31 omplication of allogeneic hematopoietic stem cell transplantation.

32 otherapy, and 42% of patients underwent stem cell transplantation.

33 d siblings has been a pivotal change in stem cell transplantation.

34 d resume quizartinib after haemopoietic stem-cell transplantation.

35 s if ineligible for autologous hematopoietic cell transplantation.

36 e to those of HLA-matched hematopoietic stem cell transplantation.

37 ous complication of allogeneic hematopoietic cell transplantation.

38 from the early 2000s followed by blood stem cell transplantation.

39 on regimen that can be applied to allogeneic cell transplantation.

40 ing complication of allogeneic hematopoietic cell transplantation.

41 tion following allogeneic hematopoietic stem cell transplantation.

42 sk of relapse after allogeneic hematopoietic cell transplantation.

43 for patients after allogeneic hematopoietic cell transplantation.

44 fects patients undergoing hematopoietic stem cell transplantation.

45 this model in unrelated donor hematopoietic cell transplantation.

46 r the routine management of GVHD during stem-cell transplantation.

47 recipients of allogeneic hematopoietic stem cell transplantation.

48 ical outcome of cultivated limbal epithelial cell transplantation.

49 r-recipient pairs undergoing allogeneic stem cell transplantation.

50 h high-dose chemotherapy and autologous stem cell transplantation.

51 iseases in the context of hematopoietic stem cell transplantation.

52 sions and overall success of allogeneic stem cell transplantations.

53 nly following allogeneic haematopoietic stem cell transplantation(2,3), may be feasible in rare insta

54 Forty-six patients received stem cell transplantation (20 autologous, 26 allogeneic).

55 After undergoing stem cell transplantation, 94% of allergen-specific IgE respo

56 poietic syndrome is allogeneic hematopoietic cell transplantation, a therapy unavailable to many pati

57 Patients proceeding to haemopoietic stem-cell transplantation after quizartinib could resume quiz

58 Autologous haematopoietic stem cell transplantation (AHSCT) has been explored as a ther

59 Autologous hematopoietic stem cell transplantation (AHSCT) with anti-thymocyte globuli

60 Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, bu

61 nd outcomes in allogeneic hematopoietic stem cell transplantation (allo-HCT) have thus far largely fo

62 Although allogeneic hematopoietic cell transplantation (allo-HCT) is currently the standar

63 tients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high inci

64 and mortality after allogeneic hematopoietic cell transplantation (allo-HCT).

65 complication after allogeneic hematopoietic cell transplantation (allo-HCT).

66 m survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their respective re

67 utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD.

68 Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was the first successfu

69 wider usage of allogeneic hematopoietic stem cell transplantation (allo-HSCT), which is an effective

70 r patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukem

71 Allogeneic hematopoietic stem cell transplantation (allo-SCT) offers cure for a variet

72 therapy followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent maintena

73 Allogeneic hematopoietic cell transplantation (alloHCT) benefits increasing numbe

74 r effects following allogeneic hematopoietic cell transplantation (alloHCT), but retrospective studie

75 relapse even after allogeneic hematopoietic cell transplantation (alloHCT).

76 malignancies, allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only available cu

77 Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative

78 Allogeneic stem cell transplantation (alloSCT) of homozygous CCR5 Delta3

79 d leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prog

80 (2020) show that hematopoietic stem cell transplantation, an established therapy, improves p

81 ived upfront therapy (14 haematopoietic stem cell transplantation and 4 chemotherapy), 4 (15%) patien

82 12%) underwent allogeneic hematopoietic stem cell transplantation and 640 (31.0%) were neutropenic at

83 ng immunocompromised zebrafish for xenograft cell transplantation and credentials the model as a new

84 Despite limited progress, stem cell transplantation and donor lymphocyte infusions show

85 Hematopoietic stem cell transplantation and gene therapy are the only curat

86 is, our patient underwent hematopoietic stem cell transplantation and is well 8 years later.

87 Hematopoietic stem cell transplantation and NF-kappaB1 pathway-targeted the

88 on were allocated to undergo allogeneic stem-cell transplantation and those with low minimal residual

89 egies to enhance the safety of hematopoietic cell transplantation and to improve patient selection/ri

90 disease after allogeneic hematopoietic stem cell transplantation and with new onset type 1 diabetes,

91 ts had received high-dose melphalan and stem cell transplantation and/or treatment with a proteasome

92 s in gene therapy, better outcomes with stem cell transplantation, and discoveries of putative new dr

93 ng malignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia were not.

94 y followed by autologous haematopoietic stem cell transplantation, and prospective trials have demons

95 age at diagnosis, age at hematopoietic stem cell transplantation, and the comorbidities that develop

96 imized intraperitoneal and periocular muscle cell transplantation; and epifluorescence and confocal i

97 alignancies or undergoing hematopoietic stem cell transplantation are vulnerable to colonization and

98 briefly discuss the state of human olfactory cell transplantation as a therapy, considering both its

99 atients with cancer receiving haematopoietic cell transplantation as they recover from chemotherapy a

100 aintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progressio

101 aluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidom

102 Autologous stem cell transplantation (ASCT) is a standard of care in eli

103 amethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therap

104 h high-dose chemotherapy and autologous stem cell transplantation (ASCT) or conventional chemotherapy

105 Autologous stem cell transplantation (ASCT) remains the standard of care

106 sity plays a key role during allogeneic stem cell transplantation (ASCT), and loss of diversity corre

107 ing considered for immediate autologous stem-cell transplantation (ASCT).

108 d reinfused after a standard autologous stem cell transplantation (ASCT).

109 itis (OM) is a frequent complication of stem cell transplantation-associated toxicity in haematologic

110 age undergoing allogenic hematopoietic stem cell transplantation at our institution.

111 Allogeneic hematopoietic cell transplantation at the time of second complete remi

112 were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced f

113 schedules in autologous haematopoietic stem cell transplantation (autoHCT) patients.

114 high-dose chemotherapy with autologous stem-cell transplantation, because of their age (>=65 years)

115 ta), and underwent allogeneic haematopoietic cell transplantation between Jan 15, 2008, and Dec 28, 2

116 y treated with allogeneic hematopoietic stem cell transplantation, but alternatives are needed for pa

117 ts with multiple myeloma ineligible for stem-cell transplantation, but further external validation is

118 as had considerable impact in pediatric stem cell transplantation, but its wider use is limited in pa

119 We sought to improve hematopoietic stem cell transplantation by developing a new mobilization st

120 ately one-fifth of patients, autologous stem cell transplantation can be considered up front or after

121 Stem cell transplantation can improve behavioral recovery aft

122 Although cell transplantation can rescue motor defects in Parkins

123 HEK293 cell transplantation caused no difference compared to SC

124 ious empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, anti-ME

125 eukaemia (two [3%]), and haematopoietic stem-cell transplantation complications (five [7%]).

126 h models were history of haematopoietic stem-cell transplantation, cumulative alkylating drug dose, a

127 The success of allogeneic hematopoietic cell transplantation depends heavily on the delicate bal

128 ions following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technolog

129 gnostic purposes such as haematopoietic stem cell transplantation donor screening or population studi

130 ause of death after allogeneic hematopoietic cell transplantation for acute leukemias.

131 ymphocytes, and allogeneic haemopoietic stem-cell transplantation for cancer treatment.

132 ndergoing chemotherapy or hematopoietic stem cell transplantation for hematological malignancy at St.

133 proof of principle for the benefits of stem cell transplantation for other fatal leukodystrophies wi

134 urvival (EFS) after allogeneic hematopoietic cell transplantation for sickle cell disease.

135 al deafness that requires hematopoietic stem cell transplantation for survival.

136 nd the curative effect of hematopoietic stem cell transplantation for the hematopoietic features of S

137 Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined immuno

138 inuous-infusion reinduction followed by stem cell transplantation forms the basis for testing new dru

139 In the patients allocated to undergo stem-cell transplantation, four relapses and three deaths wer

140 nal cure after allogeneic hematopoietic stem cell transplantation from a donor carrying a mutation in

141 affold-free constructs while enabling direct cell transplantation from in vitro culture to targeted s

142 rved after haploidentical hematopoietic stem cell transplantation (h-HSCT) with posttransplant cyclop

143 Bone marrow stem cell transplantation had not been accessible during her

144 chemotherapy and subsequent autologous stem-cell transplantation, had an Eastern Cooperative Oncolog

145 cell reconstitution after hematopoietic stem cell transplantation has been observed, we hypothesized

146 hibitors, and autologous haematopoietic stem-cell transplantation has improved outcomes for patients

147 ne therapies or that has relapsed after stem-cell transplantation have a poor prognosis.

148 phoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatmen

149 sease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting a

150 cell lymphoma ineligible for autologous stem-cell transplantation having a complete response, and mig

151 Post hematopoietic cell transplantation (HCT) autoimmune cytopenia (AIC) is

152 ciencies undergoing allogeneic hematopoietic cell transplantation (HCT) for difficult-to-control infe

153 model for OS using allogeneic hematopoietic cell transplantation (HCT) in first complete remission a

154 rtality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in the pediatric age group is

155 The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-ho

156 alovirus (CMV) infection after hematopoietic cell transplantation (HCT) is poorly understood.

157 Hematopoietic cell transplantation (HCT) is the primary curative appro

158 practices and their impact on hematopoietic cell transplantation (HCT) outcomes are poorly understoo

159 distress during their child's hematopoietic cell transplantation (HCT) process.

160 e chain reaction in allogeneic hematopoietic cell transplantation (HCT) recipients who underwent a BA

161 in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients.

162 iated with adverse outcomes in hematopoietic cell transplantation (HCT) recipients.

163 Hematopoietic cell transplantation (HCT) remains the only curative tre

164 BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the Center for Inte

165 in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy and long-term o

166 jor complication of allogeneic hematopoietic cell transplantation (HCT), mediated primarily by donor

167 ite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid

168 atients who undergo allogeneic hematopoietic cell transplantation (HCT), post-HCT clones can be donor

169 tic hemorrhagic cystitis after hematopoietic cell transplantation (HCT).

170 y reactivates after allogeneic hematopoietic cell transplantation (HCT).

171 tive conditioning regimens for hematopoietic cell transplantation (HCT).

172 r HLA class I or II mismatched hematopoietic cell transplantation (HCT).

173 High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care

174 on is a main concern after haemopoietic stem cell transplantation (HSCT) and a major cause of transpl

175 a (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with incre

176 autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was co

177 nt their first allogeneic hematopoietic stem cell transplantation (HSCT) between Jan 3, 2001, and Dec

178 tion status, and whether haematopoietic stem cell transplantation (HSCT) had been done, as well as tr

179 n clinical outcomes after hematopoietic stem cell transplantation (HSCT) has been studied, little is

180 ular engraftment following haemopoietic stem cell transplantation (HSCT) has historically been limite

181 Hematopoietic stem cell transplantation (HSCT) improves clinical outcomes i

182 utic effect of allogeneic hematopoietic stem cell transplantation (HSCT) in autoinflammatory disorder

183 s, matched sibling donor haematopoietic stem cell transplantation (HSCT) in children (offering an ove

184 findings strongly support hematopoietic stem cell transplantation (HSCT) in patients with severe pres

185 n (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with a

186 mes following allogeneic haematopoietic stem cell transplantation (HSCT) in two patients with ALSP at

187 Hematopoietic stem cell transplantation (HSCT) is a curative therapy for bl

188 Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for

189 regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for

190 nrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associated with considera

191 ogy beyond 3 months after hematopoietic stem cell transplantation (HSCT) is complex.

192 al management, allogeneic hematopoietic stem cell transplantation (HSCT) is still hampered by high mo

193 abolism (IEM), allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure.

194 Presymptomatic hematopoietic stem cell transplantation (HSCT) is the only treatment for in

195 and mortality in the post-hematopoietic stem cell transplantation (HSCT) period, IFDs, especially inv

196 is available, allogeneic hematopoietic stem cell transplantation (HSCT) should be pursued.

197 tigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson

198 relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) using donor-derived CD19 CAR

199 Hematopoietic stem cell transplantation (HSCT) was used as consolidation in

200 ore and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortez

201 compared the outcomes of hematopoietic stem cell transplantation (HSCT) with TCRalphabeta+/CD19+ dep

202 h conventional therapy or hematopoietic stem cell transplantation (HSCT), and that the poor PROs corr

203 lative 10/10 HLA-matched haematopoietic stem-cell transplantation (HSCT).

204 n pediatric recipients of hematopoietic stem cell transplantation (HSCT).

205 diotherapy and allogeneic hematopoietic stem cell transplantation (HSCT).

206 nly curative treatment is hematopoietic stem cell transplantation (HSCT).

207 plication post allogeneic hematopoietic stem cell transplantation (HSCT).

208 orbidity and mortality in hematopoietic stem cell transplantation (HSCT).

209 urs in children undergoing haemopoietic stem-cell transplantation (HSCT).

210 ell deficiency, cultivated limbal epithelial cell transplantation improves vision and ocular surface

211 al for the development of hematopoietic stem cell transplantation in alpha- and beta- mannosidosis, f

212 conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lymphoma.

213 e possible, for example, haematopoietic stem cell transplantation in FA and NBS, future early interve

214 rrow ablation followed by hematopoietic stem cell transplantation in multiple myeloma and acute myelo

215 reconstitution following hematopoietic stem cell transplantation in NIK deficiency.

216 Finally, hematopoietic stem cell transplantation in patients reduces globoid cells i

217 The HSC self-renewal defect is rescued after cell transplantation into a normal microenvironment, thu

218 he absence of an effective treatment, direct cell transplantation into the CNS to restore myelin has

219 re, we describe the procedures for xenograft cell transplantation into the prkdc(-/-), il2rgalpha(-/-

220 Allogeneic stem cell transplantation is a cornerstone of curative therap

221 Bone marrow stem cell transplantation is a potentially curative treatment

222 -derived neural progenitor cells (hiNPC) for cell transplantation is an important objective.

223 Mismatched stem cell transplantation is associated with a high risk of g

224 Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and c

225 Haemopoietic cell transplantation is established as a standard treatm

226 Overall survival following allogeneic stem cell transplantation is improving with substantial progr

227 Allogeneic hematopoietic cell transplantation is indicated for refractory hematol

228 Cell transplantation is one of numerous experimental str

229 Allogeneic hematopoietic stem cell transplantation is the only available cure.

230 Hematopoietic stem cell transplantation is the only curative option, but a

231 Allogeneic hematopoietic stem cell transplantation is the only potentially curative tr

232 At present, hematopoietic stem cell transplantation is the therapy of choice for patien

233 to engraftment after in utero hematopoietic cell transplantation (IUHCT).

234 (MM) relapsing after a prior autologous stem-cell transplantation leads to increased remission durati

235 Limbal stem cell transplantation (LSCT) and Boston keratoprosthesis

236 e with multiple relapses, hematopoietic stem cell transplantation may be considered, but its efficacy

237 Zebrafish are an ideal cell transplantation model.

238 these inflammatory mechanisms, we developed cell transplantation models in dipeptidylpeptidase-defic

239 her matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) can reduce velocities in

240 emains a major limitation of allogeneic stem-cell transplantation; not all patients have a response t

241 Encapsulated beta cell transplantation offers a potential cure for a subse

242 be made on the impact of hematopoietic stem cell transplantation on allergy transfer or cure of the

243 t, which may be advantageous for therapeutic cell transplantation or as a localised treatment for NI

244 treated with either autologous hematopoietic cell transplantation or two or more prior chemotherapy r

245 l 1 year after allogeneic hematopoietic stem-cell transplantation or until 1 year after the last dose

246 nonhematologic neoplasm, after hematopoietic cell transplantation, or as a result of germline testing

247 explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for

248 that occurs as a result of traumatic injury, cell transplantation, or tumor growth, among many others

249 morefractory, relapsed after allogeneic stem-cell transplantation, or were otherwise ineligible for a

250 ed 1,974 adult allogeneic hematopoietic stem cell transplantation patients from Beth Israel Deaconess

251 e analysis of 192 autologous peripheral stem cell transplantation patients with lymphoma and multiple

252 Hematopoietic stem cell transplantation profoundly reduces allergen-specifi

253 vival in a model of allogeneic hematopoietic cell transplantation, providing the rationale for furthe

254 a median of 8.6 years after allogeneic stem cell transplantation (range, 2-23 y) with a median inter

255 ated with solid organ and hematopoietic stem cell transplantation, rapid and accurate microbiology di

256 higher mortality in allogeneic hematopoietic cell transplantation recipients with LRTD.

257 Salvage autologous stem-cell transplantation (sASCT) in patients with multiple m

258 to receive single or tandem autologous stem-cell transplantation (SCT) after induction chemotherapy.

259 allogeneic or autologous hematopoietic stem cell transplantation (SCT) and vinblastine monotherapy.

260 h as anti-CD20 monoclonal antibodies or stem-cell transplantation, should receive antiviral prophylax

261 Spermatogonial stem cell transplantation (SSCT) is an experimental technique

262 novel targeted therapies and autologous stem cell transplantation strategies.

263 (hiPSC-CMs) have been developed for cardiac cell transplantation studies more than a decade ago.

264 y may influence the choice of donors for the cell transplantation study.

265 Allogeneic haemopoietic cell transplantation substantially reduces the long-term

266 with autologous and allogeneic haemopoietic cell transplantation suggest that HIV status does not ad

267 D) is a common complication of hematopoietic cell transplantation that negatively impacts quality of

268 jor complication of allogeneic hematopoietic cell transplantation that resembles autoimmunity, with u

269 ultiple myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NCRI-XI

270 Haematopoietic stem cell transplantation, the oral formulation cladribine an

271 chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients is st

272 chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients is st

273 loma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or

274 to improve the safety of future hPSC-derived cell transplantation therapies.

275 ion of an optochemogenetics approach in stem cell transplantation therapy after stroke for optimal ne

276 anscription factor TWIST1 for an efficacious cell transplantation therapy to induce neovascularizatio

277 ed the curative potential of allogeneic stem-cell transplantation to older adults with high-risk acut

278 loma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalid

279 (hNPCs) are a promising cell source for stem cell transplantation to treat neurological diseases such

280 oproliferative disorders, hematopoietic stem cell transplantation, treatment with steroids or other i

281 The success of allogeneic stem cell transplantation underscores the immunoresponsive na

282 ations in instances in which allogeneic stem cell transplantation using a related donor is envisioned

283 Corneal limbal epithelial stem cell transplantation using cultivated human corneal epit

284 HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphami

285 ndividual IgE responses to allergens by stem cell transplantation was 1.7% and 2.3%, respectively.

286 for PED development after hematopoietic stem cell transplantation was approximately 24 months.

287 fection in patients after hematopoietic stem cell transplantation was initiated.

288 r's syndrome treated with hematopoietic stem cell transplantation was referred for decreased vision r

289 ssociated with allogeneic hematopoietic stem cell transplantation, we evaluated 1,974 adult allogenei

290 ere otherwise ineligible for allogeneic stem-cell transplantation were enrolled.

291 r or were not candidates for autologous stem-cell transplantation were enrolled.

292 with or without allogeneic haemopoietic stem-cell transplantation were randomly assigned (2:1; permut

293 specially in the context of bone marrow stem cell transplantation where early rejection of immunologi

294 penic patients undergoing hematopoietic stem cell transplantation, who receive multiple courses of an

295 he IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR

296 acy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamid

297 dren following allogeneic hematopoietic stem cell transplantation, with adoptive transfer of adenovir

298 at least 6 months following allogeneic stem cell transplantation without steroid-refractory acute gr

299 umab to VTd before and after autologous stem-cell transplantation would improve stringent complete re

300 Hematopoietic stem cell transplantation would result in normal B-cell repop